# EDGAR Filing Document

**Accession Number:** 0001131343
**File Stem:** 0001437749-26-020373
**Filing Date:** 2026-6
**Character Count:** 7116
**Document Hash:** 440feece5ac609cb04803d05b962834f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-020373.hdr.sgml**: 20260612

**ACCESSION NUMBER**: 0001437749-26-020373

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260630

**FILED AS OF DATE**: 20260612

**DATE AS OF CHANGE**: 20260612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALTERITY THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001131343
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-49843
- **FILM NUMBER:** 261084835

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3
- **BUSINESS PHONE:** 61 3 9349 4906

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRANA BIOTECHNOLOGY LTD
- **DATE OF NAME CHANGE:** 20010105

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-163**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2026**

**Alterity Therapeutics Limited**

(Name of Registrant)

**Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia**

(Address of Principal Executive Office)

**Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.**

Form 20-F ☒ Form 40-F ☐

**This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No.** [**<u>333-251073</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm)**,** [**<u>333-248980</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm) **and** [**<u>333-228671</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm)**) and our Registration Statements on Form F-3 (Files No.** [**<u>333-274816</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm)**,** [**<u>333-251647</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm)**,** [**<u>333-231417</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm) **and** [**<u>333-250076</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm)**)**

------

**ALTERITY THERAPEUTICS LIMITED**

**(a development stage enterprise)**

The following exhibits are submitted:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 [Completion of Consolidation](ex_976191.htm)

------

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Alterity Therapeutics Limited** | **Alterity Therapeutics Limited** |
| By: | /s/ Julian Babarczy |
|  | Julian Babarczy |
|  | Chairman |

---

Date: June 12, 2026

## Exhibit 99.1

**Exhibit 99.1**

![logo.jpg](logo.jpg)

**Completion of Consolidation of Capital**

**MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA** – **12 June 2026:** <u>Alterity Therapeutics</u> (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, advises that the consolidation of the Company's issued capital on a fifty (50) to one (1) basis, as approved by shareholders at the General Meeting on 29 May 2026, has now been completed.

The Company's post-consolidation capital structure is as follows:

---

| | | |
|:---|:---|:---|
| **ASX CODE** | **QUOTED SECURITIES** | **NUMBER** |
| ATH | Ordinary fully paid shares | 217508862 |
| ATHO | Option expiring 31-Aug-2026 ex $0.50 | 18624729 |
| ATHOA | Option expiring 26-Feb-2027 ex $1.40 | 24446043 |
| **ASX CODE** | **UNQUOTED SECURITIES** | **NUMBER** |
| ATHAA | Option expiring 13-Mar-2029 ex $0.20 | 403334 |
| ATHAAE | Option expiring 29-Nov-2026 ex $1.875 | 200000 |
| ATHAAG | Option expiring 29-Nov-2026 ex $1.19 | 230000 |
| ATHAAH | Option expiring 19-Dec-2026 ex $0.525 | 160000 |
| ATHAAK | Option expiring 30-Dec-2027 ex $0.50 | 3400000 |
| ATHAAL | Option expiring 09-Jan-2031 ex $0.40 | 360000 |
| ATHAAM | Option expiring 13-Jan-2031 ex USD 0.285 | 870000 |
| ATHAB | Option expiring 13-Mar-2029 ex USD 0.155 | 1250000 |
| ATHAC | Option expiring 21-Mar-2029 ex USD 0.15 | 800004 |
| ATHAD | Option expiring 01-Jul-2030 ex $0.50 | 300000 |
| ATHAE | Option expiring 08-Aug-2030 ex $0.65 | 230000 |
| ATHAF | Option expiring 08-Aug-2030 ex USD 0.43 | 6248004 |
| ATHAG | Option expiring 26-Mar-2031 ex USD 0.285 | 1230000 |
| ATHAJ | Option expiring 15-Apr-2031 ex USD 0.302 | 4245000 |
| ATHAK | Option expiring 15-Apr-2031 ex $0.45 | 540000 |

---

Where the consolidation process resulted in a fraction of a share, any fractional entitlements have been rounded up to the nearest whole number (to a minimum of 1 security).

Holding statements have been despatched to all shareholders and option holders advising them of their holdings on a post-consolidation basis.

Normal trading (on a T+2 settlement basis) commenced today, Friday 12 June, under ASX code "ATH".

**Authorised for release by the Board of Directors of Alterity Therapeutics Limited.**

------

**About Alterity Therapeutics Limited**

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company's lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's website at <u>www.alteritytx.com</u>.

**Contacts:**

**Investors**

Elyse Shapiro

<u>ir@alteritytx.com</u>

Remy Bernarda

Investor Relations Advisory Solutions

<u>ir@alteritytx.com</u>

+1 (415) 203-6386

**Media**

Casey McDonald

Tiberend Strategic Advisors, Inc.

<u>cmcdonald@tiberend.com</u>

+1 (646) 577-8520